Immune infiltrate diversity confers a good prognosis in follicular lymphoma
AuthorsTsakiroglou, A. M.
West, Catharine M L
Linton, Kim M
AffiliationDivision of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester,UK
MetadataShow full item record
AbstractBackground: Follicular lymphoma (FL) prognosis is influenced by the composition of the tumour microenvironment. We tested an automated approach to quantitatively assess the phenotypic and spatial immune infiltrate diversity as a prognostic biomarker for FL patients. Methods: Diagnostic biopsies were collected from 127 FL patients initially treated with rituximab-based therapy (52%), radiotherapy (28%), or active surveillance (20%). Tissue microarrays were constructed and stained using multiplex immunofluorescence (CD4, CD8, FOXP3, CD21, PD-1, CD68, and DAPI). Subsequently, sections underwent automated cell scoring and analysis of spatial interactions, defined as cells co-occurring within 30 μm. Shannon's entropy, a metric describing species biodiversity in ecological habitats, was applied to quantify immune infiltrate diversity of cell types and spatial interactions. Immune infiltrate diversity indices were tested in multivariable Cox regression and Kaplan-Meier analysis for overall (OS) and progression-free survival (PFS). Results: Increased diversity of cell types (HR = 0.19 95% CI 0.06-0.65, p = 0.008) and cell spatial interactions (HR = 0.39, 95% CI 0.20-0.75, p = 0.005) was associated with favourable OS, independent of the Follicular Lymphoma International Prognostic Index. In the rituximab-treated subset, the favourable trend between diversity and PFS did not reach statistical significance. Conclusion: Multiplex immunofluorescence and Shannon's entropy can objectively quantify immune infiltrate diversity and generate prognostic information in FL. This automated approach warrants validation in additional FL cohorts, and its applicability as a pre-treatment biomarker to identify high-risk patients should be further explored. The multiplex image dataset generated by this study is shared publicly to encourage further research on the FL microenvironment.
CitationTsakiroglou A-M, Astley S, Dave M, Fergie M, Harkness E, Rosenberg A, et al. Immune infiltrate diversity confers a good prognosis in follicular lymphoma. Cancer Immunol Immunother. 2021 Apr 30
JournalCancer Immunology Immunotherapy
- The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
- Authors: Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB
- Issue date: 2016 Oct
- Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
- Authors: Xie M, Jiang Q, Zhao S, Zhao J, Ye X, Qian W
- Issue date: 2020 Aug
- A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
- Authors: Huet S, Tesson B, Jais JP, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carrère M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G
- Issue date: 2018 Apr
- Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma.
- Authors: Tsakiroglou AM, Fergie M, Oguejiofor K, Linton K, Thomson D, Stern PL, Astley S, Byers R, West CML
- Issue date: 2020 Feb
- [Prognostic study of 229 follicular lymphoma patients treated with rituximab combined with chemotherapy].
- Authors: Wang N, Xu PP, Wang L, Cheng S, Zhao WL, Sun HP
- Issue date: 2019 Jan 14